Insilico and GSK collaborate to enhance drug discovery process

Insilico Medicine, a Baltimore-based company at the forefront of artificial intelligence (AI) research for drug discovery, biomarker development and aging research announced today that it has formed a collaboration with GSK to explore how Insilico’s AI capability can enhance its drug discovery process.

About the author

Alexis Anderson

View all posts

Leave a Reply

Your email address will not be published. Required fields are marked *